乳腺癌已成為女性發(fā)病率最高的腫瘤，近年來發(fā)病人數(shù)呈逐年上升的趨勢。組蛋白乙?；侵匾谋碛^遺傳修飾之一，研究發(fā)現(xiàn)在乳腺癌病理進程中常伴隨組蛋白乙酰化酶（histone acetyltransferases，HATs）與組蛋白去乙?；福╤istone deacetylases，HDACs）的表達(dá)失衡，通過動態(tài)調(diào)控染色質(zhì)結(jié)構(gòu)和基因轉(zhuǎn)錄活性參與乳腺癌的發(fā)生發(fā)展。中醫(yī)藥在乳腺癌治療中具有多成分、多靶點的特點，顯示出獨特的治療優(yōu)勢。研究表明萜類、酚類、黃酮類、多糖類等中藥單體、中藥及復(fù)方能夠通過調(diào)控HATs和HDACs的表達(dá)水平，逆轉(zhuǎn)組蛋白乙?；惓?，進而誘導(dǎo)腫瘤細(xì)胞凋亡或焦亡，抑制乳腺癌細(xì)胞增殖、侵襲和轉(zhuǎn)移。基于目前國內(nèi)外研究現(xiàn)狀，對中藥活性成分、中藥及復(fù)方調(diào)節(jié)組蛋白乙?；綇牟煌緩桨l(fā)揮抗乳腺癌作用的機制進行綜述，以期為乳腺癌藥物的研發(fā)和應(yīng)用提供理論依據(jù)。

Breast cancer has emerged as the most prevalent malignancy among women, with its incidence showing an annual upward trend in recent years. Histone acetylation, a crucial epigenetic modification, has been found to participate in the pathogenesis and progression of breast cancer through dynamic regulation of chromatin structure and gene transcription activity, primarily mediated by the expression imbalance between histone acetyltransferases (HATs) and histone deacetylases (HDACs) during pathological processes. Traditional Chinese medicine (TCM) demonstrates unique therapeutic advantages in breast cancer treatment through its characteristics of multiple components and multiple targets. Studies have revealed that various TCM monomers, TCMs, and compound formulations containing terpenoids, phenols, flavonoids, and polysaccharides can regulate HAT and HDAC expression levels, thereby reversing aberrant histone acetylation patterns. These mechanisms ultimately induce tumor cell apoptosis or pyroptosis while inhibiting proliferation, invasion, and metastasis of breast cancer cells. This review systematically summarizes current research progress regarding the mechanisms by which TCM active components, TCMs and compound formulations exert anti-breast cancer effects through histone acetylation regulation across multiple pathways. The findings aim to provide theoretical foundations for the research and development and application of breast cancer drugs.

R285

河南省科技研發(fā)計劃聯(lián)合基金（優(yōu)勢學(xué)科培育類）重點項目（222301420024）；河南省科技攻關(guān)項目（242102310582）；河南省博士后科研項目（202103092）